Am J Respir Crit Care Med August 2023 PMID 37364283

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).

Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard, Frank Sciurba

Full text PDF Download social card

Mentions

Peak: 8 in Jun 2023

across 4 sources since Jun 2023

Extended reach

232,939

potential audience

Total likes

382

Video views

23,699

Mentions per month

Jun 2023 – Feb 2025

Where it's discussed

X / Twitter38 posts
News14 articles
YouTube2 videos
Blogs2 articles

AI synopsis

What people are saying

The discussions reflect a highly positive and impactful perception of the article, with commenters acknowledging the promising clinical trial outcomes and the drug’s potential to address unmet needs in COPD management. Words like 'revolutionary,' 'significant improvement,' and 'FDA approved' demonstrate excitement and recognition of the study’s importance, while references to trial phases and mechanisms indicate deep engagement with the scientific content.

AgreementStrong agreement

Most discussions express strong support or positive recognition of the study’s findings, highlighting the significance of ensifentrine as a new treatment option for COPD.

InterestHigh interest

Posts show high curiosity with comments about FDA approval, clinical benefits, and potential for the drug to become a breakthrough, indicating strong engagement with the research.

EngagementHigh engagement

Several posts delve into trial results, mechanism of action, and implications for patient care, demonstrating deep involvement and analysis.

ImpactHigh impact

Many discussions emphasize the potential of ensifentrine to revolutionize COPD treatment, with phrases like 'game changer,' 'breakthrough,' and references to regulatory approval hinting at a high perceived impact.

Abstract in brief

Ensifentrine is a new medication that inhibits two enzymes linked to lung function, providing benefits such as bronchodilation and reduced inflammation for patients with chronic obstructive pulmonary disease (COPD).
Two large trials (ENHANCE-1 and ENHANCE-2) showed that ensifentrine significantly improved lung function and reduced symptoms and exacerbation rates compared to a placebo, but results varied between the two trials.
The studies involved nearly 1,600 patients with moderate to severe COPD, and ensifentrine was well-tolerated, with adverse events being similar to those experienced by patients on placebo.

Read the full abstract

All mentions

Ensifentrine: New Hope for COPD Treatment and Lung Function Improvement

The FDA has approved ensifentrine for COPD maintenance treatment. This video discusses how ensifentrine works, its mechanism of action targeting lung enzymes, and promising clinical trial results demonstrating improved…

Pharmacology Insights · Feb 24, 2024 23,550 views

Dupilumab's Effect on COPD with Eosinophilia: A Phase 3 Trial Overview

This video discusses a phase 3 trial that explored dupilumab's effects on COPD patients with high eosinophil counts. Results indicated significant reductions in exacerbation rates and improvements in lung function and…

社團法人台灣家庭藥師學會 · Feb 27, 2025 149 views

carl

@physioo · X

@BiotechObserver @A_May_MD https://t.co/0GI28COkJ7

Dec 24, 2024 · 579 followers View post →

Brian Elliott MD

@BrianElliottMD1 · X

The ENHANCE studies were published in 2023, but including it because now ensifentrine has become FDA approved/available. As an inhaled PDE3/4i, it improved FEV1 and probably symptoms, without the diarrhea of roflumilast. https://t.co/pd6dVnai6s

Nov 30, 2024 · 1 like · 845 followers View post →

Matt Pavitt

@DrMattPav · X

@KingsResp ENHANCE trails assessed the impact of Ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. https://t.co/AGyKja7bBr

Sep 20, 2024 · 1 like · 949 followers View post →

edutejedor

@EduTejedor · X

#Ensifentrina: inhibidor dual de PDE 3-4 y antagonista de los receptores de adenosina. Nuevo fármaco para el EPOC desde hace 20 años. Sus EECC ENHANCE-1 (HR 0.62) y ENHANCE-2 (HR 0.58) muestran una mejoría eficacia, calidad y seguridad vs pbo https://t.co/tWJtGhJ9i9

Aug 17, 2024 · 1 like · 296 followers View post →

Uddalak Majumdar

@U_D_Majumdar · X